Based on the results of the first in-human clinical trial of ibrutinib in chronic lymphocytic leukemia (CLL) - conducted in 2010 at Weill Cornell Medicine/NewYork-Presbyterian Hospital and other centers - researchers led in part by Dr. Richard Furman moved forward with the first phase II trial of the drug. According to a five-year follow-up study recently published ... Continue reading "Ibrutinib Continues to Demonstrate Viability in Treatment of CLL"
